Suzhou Pairui Biotechnology

Suzhou Pairui Biotechnology is a clinical-stage biopharmaceutical company focused on the field of RNA epitranscriptomics, specifically targeting the RNA m6A methylation pathway. Founded in 2023 and headquartered in Suzhou Industrial Park, the company is developing a pipeline of small molecule regulators and advanced RNA editing technologies to treat cancer and skin-related conditions. Its lead candidate, SS-001, is a first-in-class small molecule RNA m6A regulator currently in Phase 2 clinical trials for the treatment of hand-foot syndrome, a common side effect of chemotherapy. Pairui's proprietary Targeted RNA Modification (TRM) platform utilizes a controllable RNA m6A demethylation editing system to provide precise therapeutic regulation with reduced off-target risks compared to traditional gene editing methods. The company's innovative approach has been recognized with awards in national entrepreneurship competitions in China.